Brief: Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency
23/09/2026 22:07
BRIEF-Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency Sept 24 (Reuters) - Arcturus Therapeutics Holdings Inc ARCT.O:
ARCTURUS THERAPEUTICS - ANNOUNCES ENCOURAGING INTERIM PHASE 2 RESULTS FROM ARCT-810 IN OTC DEFICIENCY
ARCTURUS THERAPEUTICS - ARCT-810 GENERALLY SAFE AND WELL TOLERATED IN ONGOING PHASE 2 STUDY
ARCTURUS THERAPEUTICS - TO BUY MYNEO TO IMPROVE MRNA DESIGN QUALITY
Source text: ID:nBw4rjNvLa
Further company coverage: ARCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcturus Therapeutics Holdings
See all newsBrief: Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Arcturus Q2 revenue falls sharply on CSL Seqirus deal end
Brief: Arcturus Therapeutics Q2 Net Income USD -23.785 Million
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview